• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.一种用于同时检测接受抗逆转录病毒药物治疗患者的重组人免疫缺陷病毒1型分离株中蛋白酶和逆转录酶抑制剂表型耐药性的快速方法。
Antimicrob Agents Chemother. 1998 Feb;42(2):269-76. doi: 10.1128/AAC.42.2.269.
2
Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.针对蛋白酶和逆转录酶抑制剂的快速HIV-1药物敏感性表型检测法。
J Clin Virol. 1999 Jun;13(1-2):71-80. doi: 10.1016/s1386-6532(99)00010-4.
3
Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.使用自失活病毒载体系统对HIV-1对逆转录酶、蛋白酶和整合酶抑制剂的敏感性进行表型分析。
J Med Virol. 2001 Jul;64(3):223-31. doi: 10.1002/jmv.1040.
4
Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.基于 3'Gag(p2/p7/p1/p6)/PR/RT/INT-重组病毒的新型方法，可同时定量测定对成熟、蛋白酶、逆转录酶和整合酶 HIV 抑制剂的表型耐药性：抗逆转录病毒治疗多靶点时代的有用工具。
Antimicrob Agents Chemother. 2011 Aug;55(8):3729-42. doi: 10.1128/AAC.00396-11. Epub 2011 May 31.
5
A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.一种基于重组病毒作为评估1型人类免疫缺陷病毒药物敏感性工具的新策略。
J Med Virol. 2007 Feb;79(2):127-37. doi: 10.1002/jmv.20770.
6
Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.通过基因型和重组病毒表型分析比较HIV-1变体对抗逆转录病毒药物的敏感性。
Int J Infect Dis. 2015 Aug;37:86-92. doi: 10.1016/j.ijid.2015.06.011. Epub 2015 Jun 24.
7
Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.对巴西接受高效抗逆转录病毒治疗（HAART）失败患者中发现的I型人类免疫缺陷病毒B亚型和非B亚型（F和A）进行耐药逆转录酶基因分型和表型分析。
Virology. 2000 Sep 15;275(1):107-15. doi: 10.1006/viro.2000.0487.
8
Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping.将全长人类免疫缺陷病毒1型（HIV-1）gag序列纳入用于药物敏感性表型分析的病毒重组体中。
J Virol Methods. 2002 Jul;104(2):147-60. doi: 10.1016/s0166-0934(02)00059-9.
9
Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.建立和评估常规 HIV-1 表型分析（Antivirogram®）和基于基因型计算的表型分析检测（virco®TYPE HIV-1）在蛋白酶和逆转录酶基因上对耐药性的预测能力。
Intervirology. 2012;55(2):138-46. doi: 10.1159/000332013. Epub 2012 Jan 24.
10
Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.突变蛋白酶和逆转录酶对耐抗逆转录病毒药物的1型人类免疫缺陷病毒的病毒感染性、复制及蛋白质成熟的个体贡献。
J Virol. 2001 Apr;75(7):3291-300. doi: 10.1128/JVI.75.7.3291-3300.2001.

引用本文的文献

1
Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit .协同抑制的唑类组合药物和多靶点药物
J Fungi (Basel). 2024 Oct 7;10(10):698. doi: 10.3390/jof10100698.
2
Optimization of HIV Sequencing Method Using Vela Sentosa Library on Miseq Ilumina Platform.采用 Miseq Ilumina 平台上的 Vela Sentosa 文库优化 HIV 测序方法。
Genes (Basel). 2024 Feb 19;15(2):259. doi: 10.3390/genes15020259.
3
Need assessment for HIV drug resistance testing and landscape of current and future technologies in low- and middle-income countries.低收入和中等收入国家艾滋病毒耐药性检测的需求评估以及当前和未来技术的概况
PLOS Glob Public Health. 2023 Oct 18;3(10):e0001948. doi: 10.1371/journal.pgph.0001948. eCollection 2023.
4
Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness.共同进化的多药耐药HIV-1蛋白酶和逆转录酶影响整合酶药物敏感性和复制适应性。
Pathogens. 2021 Aug 24;10(9):1070. doi: 10.3390/pathogens10091070.
5
A Computational Approach for the Prediction of Treatment History and the Effectiveness or Failure of Antiretroviral Therapy.一种预测抗逆转录病毒治疗的治疗史和有效性或失败的计算方法。
Int J Mol Sci. 2020 Jan 23;21(3):748. doi: 10.3390/ijms21030748.
6
Modeling the Amplification of Immunoglobulins through Machine Learning on Sequence-Specific Features.通过对序列特异性特征的机器学习来模拟免疫球蛋白的扩增。
Sci Rep. 2019 Jul 24;9(1):10748. doi: 10.1038/s41598-019-47173-w.
7
HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data.HIV 耐药性对逆转录酶抑制剂的预测：关注开放数据。
Molecules. 2018 Apr 19;23(4):956. doi: 10.3390/molecules23040956.
8
Using drug exposure for predicting drug resistance - A data-driven genotypic interpretation tool.利用药物暴露预测耐药性——一种数据驱动的基因型解释工具。
PLoS One. 2017 Apr 10;12(4):e0174992. doi: 10.1371/journal.pone.0174992. eCollection 2017.
9
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.用于检测对HIV-1蛋白酶、逆转录酶和整合酶抑制剂的表型耐药性的内部复制能力重组病毒检测法与参考复制缺陷重组病毒检测法之间的一致性。
J Clin Lab Anal. 2018 Jan;32(1). doi: 10.1002/jcla.22206. Epub 2017 Mar 17.
10
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.在撒哈拉以南非洲地区，基于齐多夫定的一线抗逆转录病毒治疗出现长期病毒学失败后，HIV-1胸苷类似物突变的快速积累及其表型影响
J Antimicrob Chemother. 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583.

本文引用的文献

1
A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors.一种用于快速体内分析1型人类免疫缺陷病毒对逆转录酶抑制剂敏感性的重组逆转录病毒系统。
Antimicrob Agents Chemother. 1997 Dec;41(12):2781-5. doi: 10.1128/AAC.41.12.2781.
2
A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.一种评估1型人类免疫缺陷病毒分离株药物敏感性和复制情况的新方法。
J Infect Dis. 1997 Mar;175(3):561-6. doi: 10.1093/infdis/175.3.561.
3
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.用于快速检测人类免疫缺陷病毒1型逆转录酶基因中药物选择突变的线性探针分析。
Antimicrob Agents Chemother. 1997 Feb;41(2):284-91. doi: 10.1128/AAC.41.2.284.
4
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.体内对人免疫缺陷病毒1型蛋白酶抑制剂茚地那韦的病毒抗性的遗传关联
J Virol. 1996 Dec;70(12):8270-6. doi: 10.1128/JVI.70.12.8270-8276.1996.
5
Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis.利用限制性片段长度多态性分析鉴定1型人类免疫缺陷病毒不同亚型的单一感染和双重感染。
Virus Genes. 1996;13(1):69-81. doi: 10.1007/BF00576981.
6
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.一株高效复制的1型人类免疫缺陷病毒患者毒株对核苷类似物和非核苷逆转录酶抑制剂的多重耐药性
J Infect Dis. 1996 Nov;174(5):962-8. doi: 10.1093/infdis/174.5.962.
7
Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay.通过在细胞杀伤试验中使用从患者血清产生的重组病毒来测定1型人类免疫缺陷病毒的药物敏感性。
Antimicrob Agents Chemother. 1996 Oct;40(10):2404-9. doi: 10.1128/AAC.40.10.2404.
8
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.HIV蛋白酶中突变的有序积累赋予对利托那韦的耐药性。
Nat Med. 1996 Jul;2(7):760-6. doi: 10.1038/nm0796-760.
9
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.1996年人类免疫缺陷病毒感染的抗逆转录病毒疗法。一个国际小组的建议。美国国际艾滋病协会。
JAMA. 1996 Jul 10;276(2):146-54.
10
HIV viral load markers in clinical practice.临床实践中的HIV病毒载量标志物
Nat Med. 1996 Jun;2(6):625-9. doi: 10.1038/nm0696-625.

一种用于同时检测接受抗逆转录病毒药物治疗患者的重组人免疫缺陷病毒1型分离株中蛋白酶和逆转录酶抑制剂表型耐药性的快速方法。

A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.

作者信息

Hertogs K, de Béthune M P, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R

机构信息

VIRCO, Central Virological Laboratory, Edegem, Belgium.

出版信息

Antimicrob Agents Chemother. 1998 Feb;42(2):269-76. doi: 10.1128/AAC.42.2.269.

DOI:10.1128/AAC.42.2.269
PMID:9527771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC105399/
Abstract

Combination therapy with protease (PR) and reverse transcriptase (RT) inhibitors can efficiently suppress human immunodeficiency virus (HIV) replication, but the emergence of drug-resistant variants correlates strongly with therapeutic failure. Here we describe a new method for high-throughput analysis of clinical samples that permits the simultaneous detection of HIV type 1 (HIV-1) phenotypic resistance to both RT and PR inhibitors by means of recombinant virus assay technology. HIV-1 RNA is extracted from plasma samples, and a 2.2-kb fragment containing the entire HIV-1 PR- and RT-coding sequence is amplified by nested reverse transcription-PCR. The pool of PR-RT-coding sequences is then cotransfected into CD4+ T lymphocytes (MT4) with the pGEMT3deltaPRT plasmid from which most of the PR (codons 10 to 99) and RT (codons 1 to 482) sequences are deleted. Homologous recombination leads to the generation of chimeric viruses containing PR- and RT-coding sequences derived from HIV-1 RNA in plasma. The susceptibilities of the chimeric viruses to all currently available RT and/or PR inhibitors is determined by an MT4 cell-3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide-based cell viability assay in an automated system that allows high sample throughput. The profile of resistance to all RT and PR inhibitors is displayed graphically in a single PR-RT-Antivirogram. This assay system facilitates the rapid large-scale phenotypic resistance determinations for all RT and PR inhibitors in one standardized assay.

摘要

蛋白酶（PR）抑制剂与逆转录酶（RT）抑制剂联合治疗可有效抑制人类免疫缺陷病毒（HIV）复制，但耐药变异株的出现与治疗失败密切相关。本文描述了一种用于临床样本高通量分析的新方法，该方法可通过重组病毒分析技术同时检测1型HIV（HIV-1）对RT和PR抑制剂的表型耐药性。从血浆样本中提取HIV-1 RNA，通过巢式逆转录PCR扩增包含整个HIV-1 PR和RT编码序列的2.2 kb片段。然后将PR-RT编码序列库与pGEMT3deltaPRT质粒共转染到CD4+ T淋巴细胞（MT4）中，该质粒中大部分PR（第10至99密码子）和RT（第1至482密码子）序列已被删除。同源重组导致产生嵌合病毒，其包含源自血浆中HIV-1 RNA的PR和RT编码序列。嵌合病毒对所有现有RT和/或PR抑制剂的敏感性通过基于MT4细胞的3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐的细胞活力测定法在允许高通量样本的自动化系统中进行测定。对所有RT和PR抑制剂的耐药性图谱以单一的PR-RT-抗病毒图形式以图形方式显示。该检测系统有助于在一项标准化检测中快速大规模地测定所有RT和PR抑制剂的表型耐药性。